Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 49.

Steinman, L; Bar-Or, A; Behne, J M; Benitez-Ribas, D; Chin, P S; Clare-Salzler, M; Healey, D; Kim, J I; Kranz, D M; Lutterotti, A; Martin, R; Schippling, S; Villoslada, P; Wei, C H; Weiner, H L; Zamvil, S S; Yeaman, M R; Smith, T J (2016). Restoring immune tolerance in neuromyelitis optica: Part I. Neurology: Neuroimmunology and Neuroinflammation, 3(5):e276.

Bar-Or, A; Steinman, L; Behne, J M; Benitez-Ribas, D; Chin, P S; Clare-Salzler, M; Healey, D; Kim, J I; Kranz, D M; Lutterotti, A; Martin, R; Schippling, S; Villoslada, P; Wei, C H; Weiner, H L; Zamvil, S S; Smith, T J; Yeaman, M R (2016). Restoring immune tolerance in neuromyelitis optica: Part II. Neurology: Neuroimmunology and Neuroinflammation, 3(5):e277.

Warnke, C; Wattjes, M P; Adams, O; Hartung, H‑P; Martin, R; Weber, T; Stangel, M (2016). Progressive multifokale Leukenzephalopathie. Der Nervenarzt, 87(12):1300-1304.

von Gumberz, J; Mahmoudi, M; Young, K; Schippling, S; Martin, R; Heesen, C; Siemonsen, S; Stellmann, J P (2016). Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting. PeerJ, 4:e2442.

Ray, U; Cinque, P; Gerevini, S; Longo, V; Lazzarin, A; Schippling, S; Martin, R; Buck, C B; Pastrana, D V (2015). JC polyomavirus mutants escape antibody-mediated neutralization. Science Translational Medicine, 7(306):306ra151.

Pfender, N; Martin, R (2014). Daclizumab (anti-CD25) in multiple sclerosis. Experimental Neurology, 262:44-51.

Planas, R; Martin, R; Sospedra, M (2014). Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Related Outcome Measures, 5:25-33.

Damotte, V; Guillot-Noel, L; Patsopoulos, N A; Madireddy, L; El Behi, M; De Jager, P L; Baranzini, S E; Cournu-Rebeix, I; Fontaine, B; Martin, R (2014). A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes and immunity, 15(2):126-132.

Vaughan, K; Peters, B; O'Connor, K; Martin, R; Sette, A (2014). A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data? Journal of Neuroimmunology, 267(1-2):73-85.

Lutterotti, A; Martin, R (2014). Antigen-specific tolerization approaches in multiple sclerosis. Expert Opinion on Investigational Drugs, 23(1):9-20.

Martin, R; Sospedra, M (2014). Sphingosine-1 phosphate and central nervous system. In: Oldstone, M B A; Rosen, H. Sphingosine-1-Phosphate Signaling in Immunology and Infectious Diseases. Springer: Springer, 149-170.

Abramowski, P; Otto, B; Martin, R (2014). The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS ONE, 9(3):e91970.

Mansilla, M; Comabella, M; Río, J; Castilló, J; Castillo, M; Martin, R; Montalban, X; Espejo, C (2014). Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity, 47(2):127-133.

Lutterotti, A; Yousef, S; Sputtek, A; Stürner, K H; Stellmann, J P; Breiden, P; Reinhardt, S; Schulze, C; Bester, M; Heesen, Ch; Schippling, S; Miller, S D; Sospedra, M; Martin, R (2013). Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Science Translational Medicine, 5(188):188ra75.

Pfender, N; Saccardi, R; Martin, R (2013). Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Current Treatment Options in Neurology, 15(3):270-280.

Stoop, M P; Singh, V; Stingl, C; Martin, R; Khademi, M; Olsson, T; Hintzen, R Q; Luider, T M (2013). Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. Journal of Proteome Research, 12(3):1101-1107.

Tillack, K; Naegele, M; Haueis, C; Schippling, S; Wandinger, K P; Martin, R; Sospedra, M (2013). Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. Journal of Neuroimmunology, 261(1-2):108-119.

Mohme, M; Hotz, C; Stevanovic, S; Binder, T; Lee, J H; Okoniewski, M; Sospedra, M; Eiermann, T; Rammensee, H G; Martin, R (2013). HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain, 136(Pt 6):1783-1798.

Jäger, J; Schulze, C; Rösner, S; Martin, R (2013). IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. Genes and immunity, 14(7):453-461.

Schippling, S; Kempf, C; Büchele, F; Jelcic, I; Bozinov, O; Bont, A; Linnebank, M; Sospedra, M; Weller, M; Budka, H; Martin, R (2013). JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Annals of Neurology, 74(4):622-626.

Young, K L; Brandt, A U; Petzold, A; Reitz, L Y; Lintze, F; Paul, F; Martin, R; Schippling, S (2013). Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. European Journal of Neurology, 20(5):803-811.

Abrahamsson, S V; Angelini, D F; Dubinsky, A N; Morel, E; Oh, U; Jones, J L; Carassiti, D; Reynolds, R; Salvetti, M; Calabresi, P A; Coles, A J; Battistini, L; Martin, R; Burt, R K; Muraro, P A (2013). Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain, 136(9):2888-2903.

Jelcic, I; Aly, L; Binder, T M C; Jelcic, I; Bofill-Mas, S; Planas, R; Demina, V; Eiermann, T H; Weber, T; Girones, R; Sospedra, M; Martin, R (2013). T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. Journal of Virology, 87(6):3393-3408.

Stellmann, J P; Neuhaus, A; Herich, L; Schippling, S; Roeckel, M; Daumer, M; Martin, R; Heesen, C (2012). Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS ONE, 7(11):e50347.

Saccardi, R; Freedman, M S; Sormani, M P; Atkins, H; Farge, D; Griffith, L M; Kraft, G; Mancardi, G L; Nash, R; Pasquini, M; Martin, R; Muraro, P A (2012). A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Multiple sclerosis (Houndmills, Basingstoke, England), 18(6):825-834.

Martin, R (2012). Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis. Clinical Immunology, 142(1):9-14.

Trusch, M; Tillack, K; Kwiatkowski, M; Bertsch, A; Ahrends, R; Kohlbacher, O; Martin, R; Sospedra, M; Schlüter, H (2012). Displacement chromatography as first separating step in online two-dimensional liquid chromatography coupled to mass spectrometry analysis of a complex protein sample - the proteome of neutrophils. Journal of Chromatography A, 1232:288-294.

Snowden, J A; Saccardi, R; Allez, M; Ardizzone, S; Arnold, R; Cervera, R; Denton, C; Hawkey, C; Labopin, M; Mancardi, G; Martin, R; Moore, J J; Passweg, J; Peters, C; Rabusin, M; Rovira, M; van Laar, J M; Farge, D (2012). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 47(6):770-790.

Jelcic, I; Hsu, K C; Kakalacheva, K; Breiden, P; Dupont, B; Uhrberg, M; Martin, R; Münz, C; Lünemann, J D (2012). Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Multiple Sclerosis, 18(7):951-958.

Quandt, J A; Huh, J; Baig, M; Yao, K; Ito, N; Bryant, M; Kawamura, K; Pinilla, C; McFarland, H F; Martin, R; Ito, K (2012). Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. Journal of Immunology, 189(6):2897-2908.

Planas, R; Jelčić, I; Schippling, S; Martin, R; Sospedra, M (2012). Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. European Journal of Immunology, 42(3):790-798.

Naegele, M; Tillack, K; Reinhardt, S; Schippling, S; Martin, R; Sospedra, M (2012). Neutrophils in multiple sclerosis are characterized by a primed phenotype. Journal of Neuroimmunology, 242(1-2):60-71.

Lutterotti, A; Jelcic, I; Schulze, C; Schippling, S; Breiden, P; Mazzanti, B; Reinhardt, S; DiGioia, M; Repice, A; Massacesi, L; Sputtek, A; Salinas-Riester, G; Kroeger, N; Sospedra, M; Saccardi, R; Zander, A; Martin, R (2012). No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Multiple Sclerosis Journal, 18(8):1188-1192.

Reitz, L Y; Inglese, M; Fiehler, J; Finsterbusch, J; Holst, B; Heesen, C; Martin, R; Schippling, S (2012). Quantitative T2' imaging in patients with clinically isolated syndrome. Acta Neurologica Scandinavica, 126(5):357-363.

Oberwahrenbrock, T; Schippling, S; Ringelstein, M; Kaufhold, F; Zimmermann, H; Keser, N; Young, K L; Harmel, J; Hartung, H P; Martin, R; Paul, F; Aktas, O; Brandt, A U (2012). Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Multiple sclerosis international, 2012:530305.

Schippling, S; Martin, R (2012). Stammzelltransplantation bei multipler Sklerose. In: Schmidt, R M; Hoffmann, F A. Multiple Sklerose. München: Elsevier, Urban, 67-71.

Kallweit, U; Jelcic, I; Braun, N; Fischer, H; Zörner, B; Schreiner, B; Sokolov, A A; Martin, R; Weller, M; Linnebank, M (2012). Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clinical Neuropharmacology, 35(2):77-80.

Tillack, K; Breiden, P; Martin, R; Sospedra, M (2012). T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. Journal of Immunology, 188(7):3150-3159.

Yousef, S; Planas, R; Chakroun, K; Hoffmeister-Ullerich, S; Binder, T M C; Eiermann, T H; Martin, R; Sospedra, M (2012). TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. Journal of Immunology, 189(7):3618-3630.

Tewarie, P; Balk, L; Costello, F; Green, A; Martin, R; Schippling, S; Petzold, A (2012). The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE, 7(4):e34823.

Aly, L; Yousefi, S; Schippling, S; Jelcic, I; Breiden, P; Matschke, J; Schulz, R; Bofill-Mas, S; Jones, L; Demina, V; Linnebank, M; Ogg, G; Girones, R; Weber, T; Sospedra, M; Martin, R (2011). Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain: A Journal of Neurology, 134(Pt 9):2687-2702.

Bielekova, B; Richert, N; Herman, M L; Ohayon, J; Waldmann, T A; McFarland, H; Martin, R; Blevins, G (2011). Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology, 77(21):1877-1886.

McDonald, C L; Steinbach, K; Kern, F; Schweigreiter, R; Martin, R; Bandtlow, C E; Reindl, M (2011). Nogo receptor is involved in the adhesion of dendritic cells to myelin. Journal of Neuroinflammation, 8:113.

Steinbach, K; McDonald, C L; Reindl, M; Schweigreiter, R; Bandtlow, C; Martin, R (2011). Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis. PLoS ONE, 6(11):e26341.

Brandt, A U; Oberwahrenbrock, T; Ringelstein, M; Young, K L; Tiede, M; Hartung, H P; Martin, R; Aktas, O; Paul, F; Schippling, S (2011). Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain: A Journal of Neurology, 134(Pt 11):e193; author reply e194.

Yin, Y; Li, Y; Kerzic, M C; Martin, R; Mariuzza, R A (2011). Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. The EMBO Journal, 30(6):1137-1148.

Lünemann, J D; Jelcic, I; Roberts, S; Lutterotti, A; Tackenberg, B; Martin, R; Münz, C (2008). EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. Journal of Experimental Medicine, 205(8):1763-1773.

Kaiser, W; Martin, R; Schellenberg, R; Schrader, E; Saller, R (2008). Wechseljahresbeschwerden: Cimicifuga racemosa : Cimicifuga racemosa zeigt sich als eine pflanzliche, nicht hormonale Alternative bei Wechseljahresbeschwerden. Leading Opinions. Medizin für die Frau:1-4.

Kaiser, W; Martin, R; Schellenberg, R; Schrader, E; Saller, R (2008). Cimicifuga-racemosa-Extrakt Ze 450 bei Wechseljahrbeschwerden : Eine pflanzliche, nichthormonale Alternative. Ars Medici, 17:1-4.

This list was generated on Wed Nov 22 10:59:54 2017 CET.